Spoken Alpha
GDNS
Vireo Growth Inc.
Overview
Vireo Growth Inc. operates a vertically integrated cannabis company that cultivates, manufactures, and retails cannabis products across six U.S. states—Maryland, Minnesota, Missouri, Nevada, New York, and Utah.
Vireo Growth Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $490.7M market cap.
GDNS missed consensus EPS by 0.6% in Q1 FY2026, reported Mar 30, 2026.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-127 Q&A exchanges
- Q2 FY2025Earnings2025-08-139 Q&A exchanges
- Q1 FY2025Earnings2025-05-096 Q&A exchanges
- Q4 FY2024Earnings2025-03-048 Q&A exchanges
- Q3 FY2024Earnings2024-11-136 Q&A exchanges
- Q1 FY2024Earnings2024-05-078 Q&A exchanges
- Q4 FY2023Earnings2024-04-0114 Q&A exchanges
- Q3 FY2023Earnings2023-11-146 Q&A exchanges
- Q2 FY2023Earnings2023-08-149 Q&A exchanges
- Q1 FY2023Earnings2023-05-156 Q&A exchanges
- Q4 FY2022Earnings2023-04-031 Q&A exchange
- Q3 FY2022Earnings2022-11-154 Q&A exchanges
- Q3 FY2021Earnings2021-11-1012 Q&A exchanges
- Q1 FY2021Earnings2021-05-1411 Q&A exchanges
History
Earnings history
- Q1 FY20262026-03-30EPS$0.06 vs $0.15-62.0%Rev$106.2M vs ——EODHD
- Q4 FY20252025-12-30EPS$-0.32 vs $0.30-100.0%Rev$104.5M vs ——EODHD
- Q3 FY20252025-11-11EPS$-0.04 vs $0.01-100.0%Rev$91.7M vs ——EODHD
- Q2 FY20252025-08-12EPS$-0.03 vs $-0.01-100.0%Rev$48.1M vs ——EODHD
- Q1 FY20252025-05-08EPS$-0.02 vs $-0.020.0%Rev$24.5M vs ——EODHD
- Q4 FY20242025-03-03EPS$-0.07 vs $-0.01-100.0%Rev$25.0M vs ——EODHD
- Q3 FY20242024-09-29EPS$-0.02 vs $-0.020.0%Rev$25.2M vs ——EODHD
- Q2 FY20242024-08-28EPS$0.00 vs $-0.02+100.0%Rev$25.1M vs ——EODHD
- Q4 FY20232024-03-31EPS$-0.03 vs $-0.030.0%Rev$24.1M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.03 vs $-0.05+34.0%Rev— vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.06 vs $-0.05-10.8%Rev— vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.07 vs $-0.06-16.8%Rev— vs ——EODHD
- Q4 FY20222023-03-30EPS$-0.10 vs $-0.08-18.8%Rev— vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.07 vs $-0.06-15.0%Rev— vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.05 vs $-0.05+1.0%Rev— vs ——EODHD
- Q1 FY20222022-05-10EPS$-0.11 vs $-0.06-83.3%Rev— vs ——EODHD
- Q4 FY20212022-03-10EPS$-0.13 vs $-0.03-100.0%Rev— vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.05 vs $-0.02-100.0%Rev— vs ——EODHD
- Q2 FY20212021-08-12EPS$-0.05 vs $-0.03-100.0%Rev— vs ——EODHD
- Q1 FY20212021-05-13EPS$-0.06 vs $-0.05-29.0%Rev$13.2M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-03-30 | $0.06 | $0.15 | -62.0% | $106.2M | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.32 | $0.30 | -100.0% | $104.5M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.04 | $0.01 | -100.0% | $91.7M | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.03 | $-0.01 | -100.0% | $48.1M | — | — | EODHD |
| Q1 FY2025 | 2025-05-08 | $-0.02 | $-0.02 | 0.0% | $24.5M | — | — | EODHD |
| Q4 FY2024 | 2025-03-03 | $-0.07 | $-0.01 | -100.0% | $25.0M | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-0.02 | $-0.02 | 0.0% | $25.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-28 | $0.00 | $-0.02 | +100.0% | $25.1M | — | — | EODHD |
| Q4 FY2023 | 2024-03-31 | $-0.03 | $-0.03 | 0.0% | $24.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.03 | $-0.05 | +34.0% | — | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.06 | $-0.05 | -10.8% | — | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.07 | $-0.06 | -16.8% | — | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.10 | $-0.08 | -18.8% | — | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.07 | $-0.06 | -15.0% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.05 | $-0.05 | +1.0% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.11 | $-0.06 | -83.3% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-10 | $-0.13 | $-0.03 | -100.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.05 | $-0.02 | -100.0% | — | — | — | EODHD |
| Q2 FY2021 | 2021-08-12 | $-0.05 | $-0.03 | -100.0% | — | — | — | EODHD |
| Q1 FY2021 | 2021-05-13 | $-0.06 | $-0.05 | -29.0% | $13.2M | — | — | EODHD |
Source: EODHD. GDNS reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- John MazarakisCEO1 yr 9 mo3 callsCurrent
- Tyson MacDonaldCFO1 yr 9 mo4 callsCurrent
- Joseph DuxburyChief Accounting Officer1 yr 9 mo1 callCurrent
- Sean Michael ApfelbaumGC and Corporate Secretary1 yr 1 mono recorded callsCurrent
- Kyle Eugene KingsleyCo-Executive Chairman1 yr 9 mono recorded callsCurrent
- Amber Holly ShimpaCEO0 mono recorded callsFormer
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GDNS.
$ curl https://api.spokenalpha.com/v1/companies/GDNSFAQ
Frequently asked about GDNS
Where can I find Vireo Growth Inc.'s (GDNS) earnings call transcripts?
Spoken Alpha indexes GDNS's earnings call transcripts at https://spokenalpha.com/companies/GDNS. Each call links to attributed speakers and parsed analyst Q&A. Vireo Growth Inc.'s own investor relations page is at https://investors.vireogrowth.com/home/default.aspx.
When was Vireo Growth Inc.'s most recent earnings call?
Vireo Growth Inc. (GDNS) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
What sector is GDNS in?
Vireo Growth Inc. (GDNS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).